06.01.04
Enzymotec recently developed a product line marketed under the brand carDiabeat, which is designed to fight the major risks for cardiovascular disorders of diabetes patients. carDiabeat is meant to help prevent and control oxidative stress, reduce total cholesterol and triglyceride levels, and inhibit the atherosclerotic plaque formation cascade. The product line is based on a clinically proven and a proprietary combination of enzymatically derived natural lipids. These lipids include DHA and EPA in a delivery system, which enhances their efficacy and bioavailability. carDiabeat can be applied to a variety of applications, including capsules, tablets, liquid forms, nutrition bars or functional foods.